Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
Condition: Acute Myeloid Leukemia Interventions: Drug: Dose Escalation -tagraxofusp-erzs; Drug: Dose Expansion at RP2D -tagraxofusp-erzs Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; StemlineTherapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials